✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹1,767 Cr.
P/E
31.75

Key Ratios

Market cap
Market cap
1,767 Cr
PE
PE
31.75
Prom Holding
Prom Holding
53.73 %
ROE (%)
ROE (%)
15.45
ROCE (%)
ROCE (%)
14.74
Div Yield (%)
Div Yield (%)
0.53
Sales
Sales
332 Cr
OPM (%)
OPM (%)
-
Debt to Equity
Debt to Equity
0.52
Institutions
Institutions
0.38 %
Individual < 2 lac
Individual < 2 lac
18.76 %
No. of Shareholders
No. of Shareholders
12,373

About

Hester Biosciences Limited (Hester) is the largest poultry vaccine manufacturer and one of the… Read more
Low
1251
52W Range
High
2348
  • Hester Biosciences
  • NGL Fine-Chem
  • Bajaj Healthcare
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Market Share

35 %
(as of Mar 26)
Poultry Vaccines - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Operating Profit Break-Up

Capex

Asset Break-Up - Segment

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Hester Biosciences Ltd. Business

    Hester Biosciences Limited, a premier animal healthcare company in India known for poultry vaccines. Established in 1987, it has become a top global manufacturer with Asia's largest animal biological manufacturing unit in Ahmedabad.

    Hester Biosciences major competitors are NGL Fine-Chem, Bajaj Healthcare, Kopran, Themis Medicare, Shree Ganesh Remed., Solara Active Pharma, Morepen Laboratories.
    Market Cap of Hester Biosciences is ₹1,767 Crs.
    While the median market cap of its peers are ₹1,053 Crs.

    Hester Biosciences seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material